Documente Academic
Documente Profesional
Documente Cultură
Ventricular Hypertrophy:
A Working Case Scenario of Potential
Risk and Detection
Introduction
As briefly stated in the abstract, this paper explores a scenario whereby a patient, after
examination, is determined to possess the potential for left ventricular hypertrophy (LVH). LVH
usually develops as a result of long term elevated blood pressure (Bauml and Underwood,
2010). There is a wide range of contributing factors which precipitate this cardiac disorder,
however in this particular scenario the factors of age, obesity and alcohol consumption will be
the ones of focus (Gardin et al, 1997).
Approaching strictly from an organizational standpoint, this paper will summit the scenario
in the form of a nursing assessment. The segments of this nursing assessment includes: (1) A
Case Synopsis, (2) A Health History, (3) Biographical Data, (4) Past Health History, (5) Family
History, (6) Physical Assessment, (7) A Focused Physical Assessment and (8) Finding. After the
findings, a brief review of an article addressing this condition will be presented.
As stated earlier, undetected and thusly untreated LVH most often leads to a host of lifethreatening conditions including, but not limited to, congestive heart failure, ventricular
arrhythmias, myocardial infarction, carotid arthrosclerosis, and, ultimately, cardiac death. A
thorough nursing assessment is a crucial first step in heading off these potential problems and,
hopefully, granting the patient the opportunity to live a longer and healthier life (Okin et al.,
2002).
I.
A Case Synopsis
electrocardiogram and serum cardiac enzyme test are obtained. As a result, Mr. Givens is
admitted to the cardiac care unit with an initial diagnosis of an anterior wall myocardial
infarction. Mr. Given's condition, at this point, is critical.
II.
A Health History
The Chief Complaint: I have terrible chest pain. The patient states that discomfort started
after eating dinner; the intensity of the pain woke him up from a nap. Patient is a smoker; he
states smoking approximately a pack of cigarettes a day. His recent meal was fairly large.
Patient states that he initially thought that the pain was due to indigestion, so as a result he
consumed some over-the-counter antacid, but no relief from the pain came. When the
patients condition stabilizes, a complete health history is conducted.
III.
Biographical Data
IV.
Enalapril (Vasotec) 5 mg twice a day for which he has already taken two doses. In addition,
he has consumed an antacid for- what he believed to be-indigestion.
V.
VI.
Physical Assessment
Patient's general appearance is well-developed, well-groomed but in obvious discomfort. He
sits upright clutching his chest. He is alert and responsive and oriented to person, place time
and reason for visit. Patient's vital signs are: temperature 100 degrees, pulse rate 115 beats
per minute with a strong rhythm that occasionally affords an extra beat; respiration rate at 28
(HEENT), his eyes exhibited negative periorbital edema, positive arcus senilis, funduscopic.
He exhibited negative signs of papilledema and/or hemorrhaging. Patient's thyroid was not
palpable. Evaluating respiratory systems, his lungs revealed bibasilar crackles and he has
decreased breath sounds at the bases because of his guarded respirations. He has a plus 1
peripheral pulses. Gastointestinally, his abdomen appears large, round, soft, and non-tender;
he shows positive pulsation in epigastria region but is negative for bruits or thrills.
Evaluating the musculoskeletal / neurologic systems, his sensory appears intact. He has a
plus 2 deep tendon reflexes with muscle strength bilaterally equal.
Patient possesses
bilateral hand grip, with lower extremities displaying an approximate plus 4 out of 5 muscle
strength.
VII.
Findings
The question here is, based on the assessment, what are the areas of most concern? The areas
of most concern are the patient's cardiovascular and respiratory systems. According to the
assessment the PMI is enlarged; this is due to signs of hypertension and left ventricular
hypertrophy. Mr. Given's physical findings also revealed neck vein distension and an
elevated jugular venous pressure. These findings reveal signs of right-sided heart failure.
The patient suffers from a decreased cardiac output and ineffective tissue perfusion,
improving the condition of these problems is essential to his health and future wellbeing.
This can be accomplished through medication and lifestyle changes which include weight
management, diet and ceasing smoking habits.
Overview
The authors believe that LVH recent evidence indicates that this disorder is a modifiable risk
factor that may not necessarily be entirely dependent on blood pressure control; in this much,
they review its pathogenesis, diagnosis, and treatment in coming to their conclusion. They
acknowledge that LVH is caused by a chronically increased cardiac workload whereby the
consensus in the medical community is that it is most commonly caused from hypertension.
They argue that patients who have this disorder should undergo echocardiography to screen for
LVH, using specifically the calculated left ventricular mass index. The equally argue that
electrocardiography is too insensitive to be used alone to screen for LVH. The chief argument
for hypertensive patients is that they should undergo therapy consisting of an angiotensin II
receptor blocker or an angiotensin-converting enzyme inhibitor. They contend that treatment
induced regression of LVH improves cardiovascular outcomes independent of blood pressure.
Overall it is a very informative article to read about the subject.
References
Bauml, M. A. & Underwood, D. A. (2010). Left ventricular hypertrophy: An overlooked
cardiovascular risk factor. Cleveland Clinic Journal of Medicine, 77(6), 381-387.
Gardin, J. M., et al. (1997). Left ventricular mass in the elderly. The cardiovascular health study.
Hypertension, 29, 10951103.
Okin, P.M., Wright J.T., Nieminen, M.S., et al. (2002). Ethnic differences in
electrocardiographic criteria for left ventricular hypertrophy: the LIFE study. Losartan
intervention for endpoint. Am J Hypertens, 15(8), 663671.